The U.S. Supreme Court declined to hear a challenge from pharmaceutical companies against a Biden-era plan to negotiate Medicare drug prices.
Novo Nordisk, AstraZeneca, and others argued the plan forces steep discounts and harms innovation. The justices left lower court rulings intact.
The plan targets high-cost drugs for Medicare, impacting out-of-pocket expenses for seniors. First negotiated prices took effect this year.
